- Home
- QVCGA vs INKT Comparison
QVCGA vs INKT Comparison
Compare QVCGA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QVCGA
- INKT
- Stock Information
- Founded
- QVCGA 1991
- INKT 2017
- Country
- QVCGA United States
- INKT United States
- Employees
- QVCGA N/A
- INKT N/A
- Industry
- QVCGA
- INKT Medicinal Chemicals and Botanical Products
- Sector
- QVCGA
- INKT Health Care
- Exchange
- QVCGA NYSE
- INKT Nasdaq
- Market Cap
- QVCGA 26.1M
- INKT 28.8M
- IPO Year
- QVCGA N/A
- INKT 2021
- Fundamental
- Price
- QVCGA $2.94
- INKT $62.86
- Analyst Decision
- QVCGA
- INKT Strong Buy
- Analyst Count
- QVCGA 0
- INKT 2
- Target Price
- QVCGA N/A
- INKT $37.50
- AVG Volume (30 Days)
- QVCGA 110.7K
- INKT 2.4M
- Earning Date
- QVCGA 08-07-2025
- INKT 08-12-2025
- Dividend Yield
- QVCGA N/A
- INKT N/A
- EPS Growth
- QVCGA N/A
- INKT N/A
- EPS
- QVCGA N/A
- INKT N/A
- Revenue
- QVCGA $9,800,000,000.00
- INKT N/A
- Revenue This Year
- QVCGA $2.89
- INKT N/A
- Revenue Next Year
- QVCGA $0.45
- INKT N/A
- P/E Ratio
- QVCGA N/A
- INKT N/A
- Revenue Growth
- QVCGA N/A
- INKT N/A
- 52 Week Low
- QVCGA $2.27
- INKT $4.56
- 52 Week High
- QVCGA $39.74
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- QVCGA N/A
- INKT 57.39
- Support Level
- QVCGA N/A
- INKT $6.80
- Resistance Level
- QVCGA N/A
- INKT $7.88
- Average True Range (ATR)
- QVCGA 0.00
- INKT 0.40
- MACD
- QVCGA 0.00
- INKT 0.02
- Stochastic Oscillator
- QVCGA 0.00
- INKT 58.86
About QVCGA QVC GROUP INC
QVC Group Inc is a live social shopping company with six retail brands QVC, HSN, Ballard Designs, Frontgate, Garnet Hill, Grandin Road, and other minority interests. QVC offers assortment of ,quality merchandise and classifies its products into six groups: home, apparel, beauty, accessories, electronics and jewelry. The company has three reportable segments: QxH, QVC International, and CBI. Majority of revenue is from Home products, from QxH segment. Company also operates in Japan, Germany and Other foreign countries.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.